A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics

This study will take place at multiple sites and is divided into three phases:an initial 4-week getting-to-know-you phase,a 26-week main phase where participants receive medication,and a 4-week follow-up phase.Participants will be divided into three groups:two will receive different doses of PEG-rhGH Injection,and the third will receive hGH Injection.The goal is to determine which medication works best.

NCT Number	NCT07260500
Lead Sponsor	Changchun GeneScience Pharmaceutical Co., Ltd.
Conditions	Short Stature Children Born Small for Gestational Age (SGA)
Enrollment	72 participants
Start Date	2025-11-11
Primary Completion	2026-12-23 (estimated)
Study Completion	2027-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-02-17